Share on LinkedInShare on LinkedIn

ARTICLE · 13 MAY 2020

COVID-19 – Considerations For Public Company Director Compensation

As businesses continue to navigate the health and economic challenges posed by the COVID-19 pandemic, annual shareholder meeting dates are approaching for most public companies.

United StatesCoronavirus (COVID-19)

As businesses continue to navigate the health and economic challenges posed by the COVID-19 pandemic, annual shareholder meeting dates are approaching for most public companies. Accordingly, where annual director equity grants are made on the date of the annual shareholder meeting, boards of directors should carefully consider, with guidance from their legal advisors and compensation consultants, whether any adjustments to director compensation programs are necessary in response to recent market turbulence.

We have listed key considerations we believe boards of directors should examine in connection with this review, particularly in light of the current environment of investor and activist scrutiny and the risk of Delaware breach of fiduciary duty claims related to director compensation.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from